Tuberculosis Research and Epidemiology

This study shows that pyrazinamide's bactericidal activity against Mycobacterium tuberculosis is enhanced by host-derived reactive oxygen species and thiol oxidation, highlighting the role of oxidative stress in PZA efficacy.

This study identifies Mtb outer membrane proteins using protease shaving and mass spectrometry, revealing novel vaccine targets and methods to deliver cargoes to the Mtb surface.

This study shows that impaired macrophage fatty acid metabolism limits Mycobacterium tuberculosis growth through multiple anti-microbial mechanisms.

The paper develops a new gamma interferon (IFN-γ) algorithm to improve tuberculosis diagnosis in cynomolgus macaques by reducing indeterminate cases through optimized mitogen controls and algorithm adjustments.

This study evaluates four peptides derived from EsxG·EsxH as subunit vaccines to boost BCG vaccination in mice, showing improved survival, reduced bacillary load, and less tissue damage.

The paper evaluates human-derived tuberculosis disease risk biosignatures for their predictive fidelity across preclinical models and tissues using public datasets.

This study evaluates telacebec's contribution to combination therapies against two M. tuberculosis strains in a murine model, finding synergistic effects against HN878 and antagonistic effects against H37Rv.

The paper identifies a humoral correlate of protection against tuberculosis in humans and non-human primates, showing cross-species and vaccine regimen consistency.

The paper evaluates the antimycobacterial activity of salicylic acid derivatives and shows they disrupt intrabacterial pH homeostasis in M. tuberculosis.

This study compares immune responses to drug-sensitive and drug-resistant M. tuberculosis isolates, finding differences in cytokine secretion and ROS production between PPD-positive and PPD-negative individuals.

The paper uses mathematical modeling to show that Mycobacterium tuberculosis replication in rabbit lungs is heterogeneous, with subpopulations exhibiting different growth kinetics.

This study evaluates two compounds that reduce triglyceride content in Mtb-infected macrophages but finds they do not reduce bacterial burden or inflammation in infected mice.

The paper identifies vulnerabilities in isoniazid-resistant Mycobacterium tuberculosis strains by analyzing metabolic and transcriptional changes in katG mutants.

This study characterizes the structure and function of PE11 esterase from Mycobacterium tuberculosis, showing its role in virulence and potential as a therapeutic target.

This study shows that elderly lung mucosa alters Mycobacterium tuberculosis gene expression, enhancing its metabolic adaptation and survival in alveolar epithelial cells.

The paper introduces CRESTA, a method to analyze CD4 T cell epitope specificities and phenotypes, revealing diverse responses to Mycobacterium tuberculosis.

This study validates DXS as a drug target in mycobacteria by showing its essential role in growth and sensitivity to TB drugs.

This study evaluates how bacterial growth phase and drug exposure affect bacterial load estimation methods for Mycobacterium tuberculosis.

This study shows Mtb uses SIRT2 to acquire iron, reducing immune response and increasing survival, with implications for new host-targeted therapies.

The paper identifies the GID/CTLH complex as a host determinant suppressing antimicrobial responses against intracellular bacterial infections through a CRISPR screen in Mtb-infected macrophages.

This study uses single-cell RNA-seq to show reduced type-II interferon and elevated Th17 responses in lung immune cells of diabetes-tuberculosis comorbid mice.

This study identifies breed-specific immune signatures associated with tuberculosis susceptibility in Sahiwal and crossbred cattle through transcriptomic analysis of PBMC responses to M. tuberculosis and BCG.

The paper analyzes copy number variations in 9,482 Mycobacterium tuberculosis isolates to identify lineage-specific molecular determinants associated with virulence and drug resistance.

The paper identifies a Q135K mutation in uvrA of Mycobacterium tuberculosis that confers survival advantage under oxidative stress and in macrophages, enhancing host adaptability.

This study shows that MBX-4888A, a spectinamide, shortens tuberculosis treatment in murine models by improving tissue distribution and working well with rifampin and pyrazinamide.

This study evaluates direct inhibitors of InhA (DIIs) for tuberculosis treatment, showing their efficacy comparable to isoniazid and their potential in new drug regimens.

The paper identifies a vitamin C analog, C11, that enhances anti-tuberculosis drug efficacy against M. tuberculosis by reducing mutant generation and increasing ROS production.